170838-23-0 Usage
General Description
2-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER HCL is a chemical compound consisting of a piperidine ring attached to a benzoic acid methyl ester group, and it contains a hydrochloride (HCL) salt. It is commonly used as a pharmaceutical intermediate and can be further modified to produce various medications. 2-PIPERIDIN-4-YL-BENZOIC ACID METHYL ESTER HCL may have potential applications in the development of drugs targeting central nervous system disorders, such as depression, anxiety, and schizophrenia. Its chemical structure makes it a promising candidate for further research and potential therapeutic use in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 170838-23-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,0,8,3 and 8 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 170838-23:
(8*1)+(7*7)+(6*0)+(5*8)+(4*3)+(3*8)+(2*2)+(1*3)=140
140 % 10 = 0
So 170838-23-0 is a valid CAS Registry Number.
170838-23-0Relevant articles and documents
N-SUBSTITUTED NAPHTHALENE CARBOXAMIDES AS NEUROKININ-RECEPTOR ANTAGONISTS
-
, (2008/06/13)
A compound of formula I wherein: R is alkyl; R1 is optionally substituted phenyl 2-oxo-tetrahydro-1(2H)-pyrimidinyl, or 2-oxo-1-piperidinyl; R2 is hydrogen, alkoxy, alkanoyloxy, alkoxycarbonyl, alkanoylamino, acyl, alkyl, carbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl where the alkyl groups are the same or different, hydroxy, thioacyl, thiocarbamoyl, N-alkylthiocarbamoyl, or N,N-dialkylthiocarbamoyl where the alkyl groups are the same or different. X1 and X2 are independently hydrogen or halo, provided that at least one of X1 or X2 is halo; and R3, R4, R5 and R6 are independently hydrogen, cyano, nitro, trifluoromethoxy, trifluoromethyl, or alkylsulfonyl are antagonists of at least one tachykinin receptor and are useful in the treatment of depression, anxiety, asthma, pain, inflammation, urinary incontinence and other disease conditions. Process for their preparation are described, as are compositions containing them and their use.
